Research location
Kuala Lumpur
Malaysia
Research activity in Kuala Lumpur
MalaysiaCureCurrent currently publishes aggregate city-level research activity for this location: 438 trials and 568 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Kuala Lumpur
438 linked trials · page 2 of 9Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)NCT05592938 · 2023-06-27 · 1 site observation
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 2 site observations
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 3 site observations
RECRUITING
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · 2022-11-11 · 1 site observation
RECRUITING
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationNCT05315700 · 2022-03-10 · 2 site observations
RECRUITING
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCNCT04686305 · 2021-03-09 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 2 site observations
RECRUITING
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754 · 2018-02-17 · 1 site observation
RECRUITING
PIERS and BIS, sFIT:PIGF, AdrenomedullinNCT02578810 · 2016-10-01 · 1 site observation
RECRUITING
Prospective Urban Rural Epidemiology StudyNCT03225586 · 2002-01-01 · 2 site observations
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation
NOT_YET_RECRUITING
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 · 2026-08-27 · 1 site observation
WITHDRAWN
JomCare Study - A Harm Reduction StudyNCT06794840 · 2026-04-01 · 1 site observation
NOT_YET_RECRUITING
Short-Term Effects of Sucralose and Saccharin on Blood Sugar and Gut Microbiota in Type 2 DiabetesNCT07124585 · 2026-01-30 · 1 site observation
NOT_YET_RECRUITING
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297 · 2025-07-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)NCT06317051 · 2024-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Improving Breast Health Knowledge Among Women Using a Gamified Metaverse-Based PlatformNCT06930898 · 2024-12-01 · 1 site observation
COMPLETED
An AI-based mHealth Intervention to Improve HIV TestingNCT05335096 · 2024-11-26 · 1 site observation
COMPLETED
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844 · 2024-10-15 · 2 site observations
ACTIVE_NOT_RECRUITING
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06643117 · 2024-10-03 · 1 site observation
TERMINATED
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721 · 2024-09-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754 · 2024-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Integrated Online-to-offline (O2O) Model of Care for HIV Prevention and Treatment Among Men Who Have Sex With MenNCT06373952 · 2024-05-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06159790 · 2024-04-29 · 1 site observation
COMPLETED
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873 · 2024-03-29 · 2 site observations
ACTIVE_NOT_RECRUITING
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesNCT06083675 · 2024-01-26 · 1 site observation
WITHDRAWN
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDNCT06075095 · 2024-01-11 · 1 site observation
COMPLETED
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · 2023-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate CancerNCT05653063 · 2023-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 2 site observations
ACTIVE_NOT_RECRUITING
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABANCT06020014 · 2023-11-16 · 1 site observation
COMPLETED
Testing of the Smartphone App to Enhance HIV Prevention Cascade Among Malaysian MSMNCT05044013 · 2023-11-15 · 1 site observation
COMPLETED
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 2 site observations
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsNCT05801029 · 2023-07-18 · 2 site observations
ACTIVE_NOT_RECRUITING
MHealth HIV Prevention for Transgender WomenNCT05271097 · 2023-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerNCT05908734 · 2023-05-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 2 site observations
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
Testing of the JomPrEP App for HIV Prevention Among Malaysian MSMNCT05325476 · 2023-04-11 · 2 site observations
COMPLETED
Adherence and Quality of Life Across Three Different Intermittent Fasting Protocols in Obese Working WomenNCT07804329 · 2023-04-01 · 1 site observation
COMPLETED
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)NCT05526755 · 2023-03-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)NCT05755906 · 2023-02-27 · 1 site observation
COMPLETED
First in Human Study of AZD9592 in Solid TumorsNCT05647122 · 2022-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNCT05462717 · 2022-09-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05 · 3 site observations
ACTIVE_NOT_RECRUITING
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.